Amended Current Report Filing (8-k/a)
June 02 2020 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K/A
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 2, 2020 (April 17, 2020)
CytoDyn Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-49908
|
|
83-1887078
|
(State or other jurisdiction
of incorporation)
|
|
(SEC File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
1111 Main Street, Suite 660
Vancouver, Washington
|
|
|
|
98660
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrants telephone number, including area code: (360)
980-8524
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
None
|
|
None
|
|
None
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On April 23, 2020, CytoDyn Inc. (the Company) filed a Current Report
on Form 8-K to announce the appointment of a new independent director, Samir R. Patel, M.D., on April 17, 2020 (the Original Filing), to the Companys Board of Directors
(Board). At the time of the Original Filing, the Company had not made a determination regarding Board Committee assignments for Dr. Patel.
On May 27, 2020, the Board appointed Dr. Patel to the Boards Nominating and Governance Committee as its chair.
Other than the preceding disclosure, no other changes have been made to the Original Filing pursuant to this Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CytoDyn Inc.
|
|
|
|
|
June 2, 2020
|
|
|
|
By:
|
|
/s/ Michael D. Mulholland
|
|
|
|
|
|
|
Name: Michael D. Mulholland
|
|
|
|
|
|
|
Title: Chief Financial Officer
|
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Sep 2024 to Oct 2024
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Oct 2023 to Oct 2024